<h2 dir="ltr">Ovarian Cancer</h2>
Ovarian cancer is a malignant tumor that begins in the ovaries, often going undetected until it has spread within the pelvis and abdomen. It is one of the most lethal gynecologic cancers due to late diagnosis. Common symptoms include bloating, pelvic pain, and changes in urinary or bowel habits. Treatment typically involves surgery and chemotherapy.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total incident cases of Ovarian Cancer
</li>
<li dir="ltr" aria-level="1">
Age-specific cases of Ovarian Cancer&nbsp;
</li>
<li dir="ltr" aria-level="1">
Type-specific Cases of Ovarian Cancer&nbsp;
</li>
<li dir="ltr" aria-level="1">
Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer
</li>
<li dir="ltr" aria-level="1">
Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/ovarian-cancer-epidemiology-forecast">Ovarian Cancer Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, there were approximately 61K incident cases of ovarian cancer in the 7MM.
</li>
<li dir="ltr" aria-level="1">
Over 90% of malignant ovarian tumors are epithelial in nature.
</li>
<li dir="ltr" aria-level="1">
The US recorded the highest number of high- and low-grade serous ovarian cancer cases, totaling nearly 37.6K.
</li>
<li dir="ltr" aria-level="1">
MAPK mutations (BRAF/KRAS/NRAS/NF1) are most common in low-grade serous ovarian cancer (LGSOC), with the highest cases in EU4 and the UK.
</li>
<li dir="ltr" aria-level="1">
HRD (gLOH &ge;16%) mutations were more frequent in high-grade serous ovarian cancer (HGSOC) than in MAPK-mutated LGSOC.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/ovarian-cancer-market">Ovarian Cancer Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the US led the ovarian cancer market in the 7MM with a value of ~USD 2 billion.
</li>
<li dir="ltr" aria-level="1">
Among EU4 and the UK, Germany had the largest market share, while Spain had the lowest.
</li>
<li dir="ltr" aria-level="1">
Low-grade serous ovarian cancer has a high unmet need, with only one FDA-approved treatment: TAFINLAR + MEKINIST.
</li>
<li dir="ltr" aria-level="1">
Avutometinib + Defactinib is anticipated to receive approval in 2025 for LGSOC.
</li>
<li dir="ltr" aria-level="1">
In 2024, the HGSOC 1L market was valued at ~USD 1 billion, while the LGSOC 1L market stood at ~USD 3.2 million.
</li>
</ul>
<h3 dir="ltr">Ovarian Cancer Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
The increasing number of ovarian cancer cases, particularly among women aged 50 and above, is driving demand for effective diagnostic tools and treatment options.
</li>
<li dir="ltr" aria-level="1">
The development of PARP inhibitors, monoclonal antibodies, and personalized therapies is revolutionizing treatment, improving progression-free survival, and attracting investment in R&amp;D.
</li>
</ul>
<h3 dir="ltr">Ovarian Cancer Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Ovarian cancer is often diagnosed at an advanced stage due to vague symptoms and lack of reliable screening, limiting treatment efficacy and survival rates.
</li>
<li dir="ltr" aria-level="1">
The high cost of advanced therapies and limited access in low- and middle-income regions pose significant barriers to equitable ovarian cancer care.
</li>
</ul>
<h3 dir="ltr">Ovarian Cancer Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
Avutometinib + defactinib
</li>
<li dir="ltr" aria-level="1">
Relacorilant
</li>
<li dir="ltr" aria-level="1">
IMFINZI
</li>
<li dir="ltr" aria-level="1">
Rinatabart sesutecan
</li>
<li dir="ltr" aria-level="1">
Olvimulogene nanivacirepvec
</li>
<li dir="ltr" aria-level="1">
Nemvaleukin alfa
</li>
<li dir="ltr" aria-level="1">
Catequentinib
</li>
<li dir="ltr" aria-level="1">
Raludotatug deruxtecan
</li>
<li dir="ltr" aria-level="1">
Luveltamab tazevibulin
</li>
<li dir="ltr" aria-level="1">
Patritumab deruxtecan
</li>
<li dir="ltr" aria-level="1">
TORL-1-23
</li>
<li dir="ltr" aria-level="1">
Azenosertib (ZN-c3) + Niraparib
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight">Ovarian Cancer Key Players</a></h3>
<ul>
<li dir="ltr" aria-level="1">
pharma&amp; GmbH&nbsp;
</li>
<li dir="ltr" aria-level="1">
GlaxoSmithKline (GSK)
</li>
<li dir="ltr" aria-level="1">
Abbvie
</li>
<li dir="ltr" aria-level="1">
Eli Lilly
</li>
<li dir="ltr" aria-level="1">
Novartis
</li>
<li dir="ltr" aria-level="1">
Roche
</li>
<li dir="ltr" aria-level="1">
Verastem Oncology
</li>
<li dir="ltr" aria-level="1">
Corcept Therapeutics
</li>
<li dir="ltr" aria-level="1">
AstraZeneca
</li>
<li dir="ltr" aria-level="1">
Genmab
</li>
<li dir="ltr" aria-level="1">
Genelux Corporation
</li>
<li dir="ltr" aria-level="1">
Mural Oncology
</li>
<li dir="ltr" aria-level="1">
Daiichi Sankyo
</li>
<li dir="ltr" aria-level="1">
Merck
</li>
<li dir="ltr" aria-level="1">
Sutro Biopharma
</li>
<li dir="ltr" aria-level="1">
Bristol-Myers Squibb
</li>
</ul>
And others.

Ovarian Cancer Market

Ovarian Cancer Market Infographics

Ovarian Cancer Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape